Climb Bio, Inc.
Clym Therapeutics, Inc. (NASDAQ: CLYM) is a clinical-stage biotechnology company developing potential best-in-class therapeutics for patients with immune-mediated diseases. The company focuses on building a pipeline through strategic acquisition and in-licensing of product candidates with clear biological rationale,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Climb Bio, Inc. does
In the company’s own words
Clym Therapeutics, Inc. (NASDAQ: CLYM) is a clinical-stage biotechnology company developing potential best-in-class therapeutics for patients with immune-mediated diseases. The company focuses on building a pipeline through strategic acquisition and in-licensing of product candidates with clear biological rationale, well-defined development pathways, and potential to address multiple indications. More information about the company is available at www.clymtherapeutics.com.
The company's lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells. Budoprutug targets CD19 expression across multiple B-cell lineages, potentially enabling broader and more durable depletion of pathogenic B cells compared to existing therapies. The company has focused initial development of budoprutug on three indications: primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. The company received FDA clearance for a Phase 2 clinical trial in primary membranous nephropathy in March 2025 and achieved first-patient-in in November 2025. Additionally, budoprutug has received FDA clearance for Phase 1b/2a and Phase 1b clinical trials in immune thrombocytopenia and systemic lupus erythematosus, respectively. The company is also advancing a high-concentration subcutaneous formulation of budoprutug to provide differentiated convenience and potential commercial advantages.
The company's second product candidate, CLYM116, is a next-generation anti-APRIL monoclonal antibody for treating IgA nephropathy and other B-cell mediated diseases. CLYM116 employs a unique mechanism that prevents APRIL signaling through potent blocking and lysosomal degradation. The company obtained rights to CLYM116 through a license agreement with Beijing Mabworks Biotech Co., Ltd. and has worldwide development and commercialization rights outside Greater China. CLYM116 initiated a Phase 1 clinical trial in healthy volunteers in November 2025.
The company estimates more than 500,000 patients in the United States across its four initial target indications and approximately 2.0 million people living with immune-mediated diseases that its product candidates could potentially benefit. The company acquired Tenet Medicines, Inc. to build its pipeline and continues to evaluate external opportunities aligned with its strategy in immune-mediated diseases and nephrology.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WELLESLEY HILLS, MA
- Fiscal year end
- December
- CIK
- 1768446
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Climb Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Climb Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Climb Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Climb Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Climb Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”